Novo Nordisk has won a Committee for Medicinal Products for Human Use (CHMP) endorsement for a higher-dose version of its diabetes drug liraglutide that can be used to treat obesity. The Danish ...

The European Medicines Agency’s (EMAs) Committee for Medicinal Products for Human Use (CHMP) has recommended extending the use of Stallergenes Greer’s oral immunotherapy, Palforzia (defatted ...

Barclays notes that SpringWorks Therapeutics’ Ogsiveo was included on today’s Committee for Medicinal Products for Human Use agenda, which could lead to a positive opinion for ...

Vertex Pharmaceuticals VRTX announced that the European Commission (EC) has expanded the label of its blockbuster cystic ...

The European Medicines Agency's Committee for Medicinal Products for Human Use on Friday adopted a negative opinion on Kisunla, citing the risk of potentially fatal events due to amyloid-related ...

PRINCETON, N.J., March 28, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of a subcutaneous formulation of Opdivo across multiple previously ...

The agency’s Committee for Medicinal Products for Human Use said Lilly can ask for a re-examination of its opinion. Lilly said Friday that it hopes discussions about the drug continue with the ...

European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against a marketing authorization for the drug’s use in early symptomatic Alzheimer’s disease.

Shares of Ascendis Pharma (ASND) are down $5.82, or 4%, to $155.33 in morning trading in New York. The move lower began near the open and may ...

On April 2, 2025, Accord received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for two denosumab biosimilars: OSVYRTI and JUBEREQ.

The agency’s Committee for Medicinal Products for Human Use said Lilly can ask for a re-examination of its opinion. Lilly said Friday that it hopes discussions about the drug continue with the agency ...